| Study | Sample Size | Tumor Type | Duration of Follow-Up | Number (%) with Optic Neuropathy at End of Follow-Up | Predictors of Optic Neuropathy after Treatment |
| Sagoo et al. 2007 [10] | 37 patients | Circumpapillary choroidal melanoma | Mean 52 months, median 46 months | 9/37 (24.3%) | -- |
| Sagoo et al. 2008 [11] | 141 patients | Juxtapapillary choroidal melanoma overhanging optic disc | Mean 56 months | 57/141 (40.4%) | -- |
| Gunduz et al. 2010 [12] | 24 patients | Choroidal melanoma treated with ruthenium brachytherapy alone | -- | 1/24 (4.1%) | -- |
| Verschueren et al. 2010 [13] | 430 patients | Choroidal melanoma | Median 50 months | 7/430 (1.6%) | -- |
| Finger et al. 2012 [16] | 24 patients | Choroidal melanomas within 1.5 mm of optic disc treated with slotted radiotherapy | Mean 23 months | 15/24 (62.5%) | -- |
| Berry et al. 2013 [17] | 82 patients | Medium sized choroidal melanomas | Median 46.8 months | 12/82 (14.6%) | -- |
| Krema et al. 2013 [38] | 30 patients | Posterior tumor margin 0 - 2.5 mm from optic disc | -- | 40% | -- |
| Semenova et al. 2013 [19] | 72 patients | Small choroidal melanomas | Mean 54 months | 15/72 (20.8%) | Subfoveal or juxtapapillary tumor location |
| Sagoo et al. 2014 [32] | 650 eyes | Juxtapapillary choroidal melanoma | Median 40 months | 61% at 5 years | Plaque size |
| Semenova et al. 2014 [20] | 47 patients | T3 or T4 sized choroidal melanomas treated with palladium brachytherapy | Median 47 months | 24/47 (51%) | -- |